schizophrenia

FDA approves first pill that can be tracked when ingestedFDA approved the first drug in the United States that has a digital ingestion tracking system, which records when the medication was taken.
How to target high-risk populations with behavioral healthHere are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.
Addressing unique medication adherence issues for patients with schizophrenia
Addressing unique medication adherence issues for patients with schizophrenia
Big savings expected with new generic antipsychoticFDA tentatively approved the abbreviated new drug application (ANDA) for generic quetiapine fumarate extended-release tablets (brand Seroquel XR, AstraZeneca) to treat schizophrenia and manic/mixed episodes associated with bipolar disorder.
Do flame retardants increase risk of thyroid disease?Are women who exposed to flame retardants at greater risk of thyroid disease? Plus: A look at the potential connection between maternal smoking status and risk of the child developing schizophrenia. Also, can telephone therapy help menopausal women get better sleep?
Injectable schizophrenia drug gets FDA green lightFDA has approved aripiprazole lauroxil (Aristada, Alkermes) extended-release injectable suspension for the treatment of adults with schizophrenia.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
FDA approves cariprazine for treatment of schizophreniaFDA has approved cariprazine (Vraylar, Allergan and Gedeon Richter Plc.) for the treatment of schizophrenia and bipolar I disorder in adults.
FDA accepts NDA for first 'digipill'Proteus Digital Health along with the pharmaceutical company, Otsuka, has submitted the first Digital Medicine New Drug Application (NDA) for the combination tablet of Abilify (aripiprazole) embedded with a Proteus ingestible sensor.
New treatment approved for bipolar disorder, schizophreniaFDA has approved cariprazine (Vraylar) capsules, an atypical antipsychotic, indicated for the treatment of adults with schizophrenia as well as bipolar I disorder, based on controlled trials of more than 2,700 individuals.